A Study of Radiation Therapy With Pembrolizumab and Olaparib in Women Who Have Triple-Negative Breast Cancer
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether adding pembrolizumab, with or without
olaparib, to standard radiation therapy is a safe and effective treatment for triple-negative
breast cancer/TNBC.